DNA Bioscience embroiled in UK political row
This article was originally published in Clinica
Executive Summary
UK genetic testing company DNA Bioscience is at the centre of a political row over the directorship of a government minister who's department has been in discussions with it over future supply contracts. The current secretary for work and pensions, David Blunkett, acquired a 3% share in DNA Bioscience and joined as non-executive director in April 2005, during a short period when he was not in government. A House of Commons code of conduct requires former ministers to consult the Advisory Committee on Business Appointments (ACBA) - an internal regulatory body set up to reduce the risk of conflicts of interest - before taking up professional positions in industry within two years of leaving office.
You may also be interested in...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.